Merck Launches First Commercially Available Equine-Specific Multiplex Assay for Protein Biomarkers
Merck, a leading science and technology company, today announced the global launch of the first...
US FDA Expands IMBRUVICA (ibrutinib) Label to Include Overall Survival Data in Previously Untreated...
AbbVie a global biopharmaceutical company announced the U.S. Food and Drug Administration (FDA) updated the...
Allergan and Richter Announce Positive Phase III Results for Ulipristal Acetate 5 and 10...
Phase III study met all co-primary and secondary endpoints and achieved statistically significant resultsWorld pharma...
Successful ExCeL debut for Infrarail and CITE 2016
With unprecedented levels of rail investment and the rise of national infrastructure up the political...
Reed Sinopharm Hosts World’s Largest Healthcare Event – tHIS in Shanghai
SHANGHAI, April 21, 2016 /PRNewswire/ -- The Health Industry Summit (tHIS) 2016 opened in Shanghai...
AstraZeneca completes divestment of Imdur to China Medical System Holdings
AstraZeneca announced that it has completed the divestment of the global rights to Imdur, outside...
European Medicines Agency Issues Positive Opinion for the Use of IMBRUVICA® (ibrutinib)
AbbVie, a global biopharmaceutical company, announced that the Committee for Medicinal Products for Human Use...
Sunovion Pharmaceuticals Inc reports Two Phase 3 Clinical Studies for People with Moderate-to-Very Severe...
The GOLDEN-3 and GOLDEN-4 Phase 3 trials evaluating SUN-101/eFlow® in people with moderate-to-very severe COPD...
Biogen Appoints Michael Ehlers Executive Vice President, Research and Development
Biogen announced the appointment of Michael Ehlers, M.D., Ph.D., as executive vice president, Research and...
Mallinckrodt announces H.P. Acthar Gel Health Economic Data Presented at the Academy of...
Mallinckrodt plc a leading global specialty biopharmaceutical company announced the results from three Mallinckrodt-sponsored retrospective...